Table 1:
Patient, Disease and Transplant Characteristics
| 8/8 Match or HLA-DQ Mismatch MUD (N=351) | ≤7/8 at A, B, C, DR or Multiple Mismatch MMUD (N=131) | Total (N=482) | P value | |
|---|---|---|---|---|
|
| ||||
| Age at HSCT, years | <0.001 | |||
| Median | 54 | 45 | 52 | |
| Interquartile range | 43, 61 | 32, 57 | 39, 61 | |
| Range | (18–73) | (18–71) | (18–73) | |
| <50 | 131 (37.3%) | 76 (58%) | 207 (42.9%) | <0.001 |
| 50–59 | 107 (30.5%) | 29 (22.1%) | 136 (28.2%) | |
| 60+ | 113 (32.2%) | 26 (19.8%) | 139 (28.8%) | |
| Recipient sex | 0.063 | |||
| Male | 181 (51.6%) | 80 (61.1%) | 261 (54.1%) | |
| Female | 170 (48.4%) | 51 (38.9%) | 221 (45.9%) | |
| Year of HCT | 0.19 | |||
| 2005 | 5 (1.4%) | 2 (1.5%) | 7 (1.5%) | |
| 2006 | 23 (6.6%) | 8 (6.1%) | 31 (6.4%) | |
| 2007 | 35 (10%) | 14 (10.7%) | 49 (10.2%) | |
| 2008 | 40 (11.4%) | 17 (13%) | 57 (11.8%) | |
| 2009 | 53 (15.1%) | 23 (17.6%) | 76 (15.8%) | |
| 2010 | 43 (12.3%) | 23 (17.6%) | 66 (13.7%) | |
| 2011 | 61 (17.4%) | 10 (7.6%) | 71 (14.7%) | |
| 2012 | 57 (16.2%) | 16 (12.2%) | 73 (15.1%) | |
| 2013 | 34 (9.7%) | 18 (13.7%) | 52 (10.8%) | |
| Female donor to male recipient | 0.068 | |||
| Yes | 44 (12.5%) | 25 (19.1%) | 69 (14.3%) | |
| No | 307 (87.5%) | 106 (80.9%) | 413 (85.7%) | |
| Diagnosis | 0.82 | |||
| Acute Myeloid Leukemia | 164 (46.7%) | 53 (40.5%) | 217 (45%) | |
| Acute Lymphocytic Leukemia | 50 (14.2%) | 24 (18.3%) | 74 (15.4%) | |
| Chronic Myeloid Leukemia | 11 (3.1%) | 5 (3.8%) | 16 (3.3%) | |
| Chronic Lymphocytic Leukemia | 9 (2.6%) | 3 (2.3%) | 12 (2.5%) | |
| Leukemia, Other | 12 (3.4%) | 5 (3.8%) | 17 (3.5%) | |
| Myelodysplastic Syndrome | 38 (10.8%) | 10 (7.6%) | 48 (10%) | |
| Myeloproliferative Disorder | 16 (4.6%) | 5 (3.8%) | 21 (4.4%) | |
| Non-Hodgkin Lymphoma | 45 (12.8%) | 23 (17.6%) | 68 (14.1%) | |
| Hodgkin Lymphoma | 3 (0.9%) | 1 (0.8%) | 4 (0.8%) | |
| Multiple Myeloma | 3 (0.9%) | 2 (1.5%) | 5 (1%) | |
| Disease risk index | 0.91 | |||
| Low Risk | 16 (4.6%) | 6 (4.6%) | 22 (4.6%) | |
| Intermediate Risk | 191 (54.4%) | 75 (57.3%) | 266 (55.2%) | |
| High Risk | 122 (34.8%) | 41 (31.3%) | 163 (33.8%) | |
| Very High | 22 (6.3%) | 9 (6.9%) | 31 (6.4%) | |
| Conditioning intensity | 0.002 | |||
| Reduced Intensity | 215 (61.3%) | 60 (45.8%) | 275 (57.1%) | |
| Myeloablative | 136 (38.7%) | 71 (54.2%) | 207 (42.9%) | |
| GVHD prophylaxis | <0.001 | |||
| Tacrolimus, Sirolimus | 278 (79.2%) | 35 (26.7%) | 313 (64.9%) | |
| Tacrolimus, Sirolimus, +MTX | 49 (14%) | 77 (58.8%) | 126 (26.1%) | |
| Tacrolimus, Sirolimus, +ATG | 24 (6.8%) | 19 (14.5%) | 43 (8.9%) | |
| Stem cell source | - | |||
| Peripheral blood stem cells | 351 (100%) | 131 (100%) | 482 (100%) | |
| ABO blood group compatibility | 0.96 | |||
| ABO compatible | 162 (46.2%) | 62 (47.3%) | 224 (46.5%) | |
| Minor mismatch (donor is O) | 71 (20.2%) | 27 (20.6%) | 98 (20.3%) | |
| Major mismatch (recipient is O) | 80 (22.8%) | 27 (20.6%) | 107 (22.2%) | |
| Bidirectional (none are O) | 38 (10.8%) | 15 (11.5%) | 53 (11%) | |
| Donor/Recipient CMV serostatus | 0.026 | |||
| D−/R− | 44 (12.5%) | 10 (7.6%) | 54 (11.2%) | |
| D−/R+ | 165 (47%) | 49 (37.4%) | 214 (44.4%) | |
| D+/R− | 30 (8.5%) | 12 (9.2%) | 42 (8.7%) | |
| D+/R+ | 112 (31.9%) | 60 (45.8%) | 172 (35.7%) | |
| DQB1 | 0.10 | |||
| 1 | 22 (6.3%) | 14 (10.7%) | 36 (7.5%) | |
| 2 | 329 (93.7%) | 117 (89.3%) | 446 (92.5%) | |
| Karnofsky performance status % | 0.027 | |||
| 90–100 | 198 (56.4%) | 88 (67.2%) | 286 (59.3%) | |
| 70–80 | 87 (24.8%) | 18 (13.7%) | 105 (21.8%) | |
| Unknown | 66 (18.8%) | 25 (19.1%) | 91 (18.9%) | |
| HCT comorbidity index | 0.94 | |||
| 0 | 157 (44.7%) | 56 (42.7%) | 213 (44.2%) | |
| 1–2 | 79 (22.5%) | 30 (22.9%) | 109 (22.6%) | |
| >2 | 49 (14%) | 21 (16%) | 70 (14.5%) | |
| Unknown | 66 (18.8%) | 24 (18.3%) | 90 (18.7%) | |